Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +46.08%
#3 Glidr Glidr +35.94%
#4 Cysic Cysic +32.50%
#5 Walrus Walrus +23.65%
#6 Tutorial Tutorial +23.18%
#7 Enso Enso +18.12%
#8 Humanity Humanity +18.02%
#9 Codatta Codatta +14.33%
#10 Huma Finance Huma Finance +13.74%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Classement en actions #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Prix de l'action
$0.6
Dernière synchronisation: 2024-08-14
Capitalisation boursière
$2.09M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
SG
Échange ASLAN Pharmaceuticals Limited (ASLN)

Catégorie

Healthcare
Bénéfices pour ASLAN Pharmaceuticals Limited (ASLN)
Bénéfices en Mar 2024 TTM : $-34.90M
Selon les derniers rapports financiers de ASLAN Pharmaceuticals Limited, les bénéfices actuels de l'entreprise sont de $-34.90M. En 2022, l'entreprise a réalisé un bénéfice de $-51.28M, une diminution par rapport à celui de 2021 qui était de $-31.59M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour ASLAN Pharmaceuticals Limited de 2014 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-34.90M -20.84%
2023 $-44.09M -14.03%
2022 $-51.28M 62.34%
2021 $-31.59M 86.14%
2020 $-16.97M -63.63%
2019 $-46.66M 10.64%
2018 $-42.17M 3.58%
2017 $-40.71M 352.17%
2016 $-9.00M -32.43%
2015 $-13.33M 80.95%
2014 $-7.36M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -15,214.03%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,689.14%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -8,712.20%
BE